Topical CBD reduced the size and accelerated the healing of recurrent ulcers in a new randomized controlled trial published in the journal BMC Complementary Medicine and Therapies
Titled Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial, the study was conducted by researchers at the Ministry of Public Health Thailand and Chulalongkorn University.
“Although topical steroids constitute the first-line therapy for recurrent aphthous ulcers (RAUs), their long-term use often leads to candidiasis”, states the study. “Although cannabidiol (CBD) can be an alternative for pharmacologically managing RAUs due to its analgesic and anti-inflammatory in vivo effects, there is a lack of clinical and safety trials concerning its use.”
With this in mind, the aim of this study “was to evaluate the clinical safety and efficacy of topical 0.1% CBD for managing RAU.”
Continue reading